Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 12/20 | 0.55 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.52 |
| ▸ | LAP3 | P28838 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16654259 | 0.98 | FDPS (0.56) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL7078962 | 0.89 | GGPS1 (0.51) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL6240282 | 0.78 | FDPS (0.55) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL6238377 | 0.78 | FDPS (0.55) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL6241145 | 0.78 | FDPS (0.55) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL27984268 | 0.76 | FDPS (0.62) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL9787452 | 0.74 | FDPS (0.52) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL1533943 | 0.71 | LPAR1 (0.96) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL3414399 | 0.71 | FDPS (1.00) | FDPSSMPD1LPAR1LPAR3GGPS1 | |
| SCHEMBL8672279 | 0.70 | FDPS (0.64) | FDPSSMPD1LPAR1LPAR3GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280490-A1 | METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION | CYVAX, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-2286795-B1 | Method of producing a cationic liposomal preparation comprising a lipophilic compound | SYNCORE BIOTECHNOLOGY CO LTD (TW) | 2016-10-26 | — | — | EP | disclosed |
| US-9238021-B2 | Method of producing a cationic liposomal preparation comprising a lipophilic compound | MEDIGENE AG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-20150359869-A1 | METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION | CYVAX INC (US) | 2015-12-17 | — | — | US | disclosed |
| EP-1530465-B2 | METHOD OF PRODUCING A CATIONIC LIPOSOMAL PREPARATION COMPRISING A LIPOPHILIC COMPOUND | MEDIGENE AG (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20150104500-A1 | Methods and Compositions for Preventing a Condition | CYVAX, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20140205657-A1 | METHOD OF PRODUCING A CATIONIC LIPOSOMAL PREPARATION COMPRISING A LIPOPHILIC COMPOUND | MEDIGENE AG (DE) | 2014-07-24 | — | — | US | disclosed |
| US-8663606-B2 | Method of producing a cationic liposomal preparation comprising a lipophilic compound | MEDIGENE AG (DE) | 2014-03-04 | — | — | US | disclosed |
| WO-2014028644-A1 | METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION | CYVAX, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-8557248-B2 | Methods and compositions for treating malaria | CYVAX, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2277507-A1 | Method of producing a cationic liposomal preparation comprising a lipophilic compound | MediGene AG (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-7794747-B2 | Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes | MEDIGENE ONCOLOGY GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20100178243-A1 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system | MEDIGENE AG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-2108362-A2 | Method of producing a cationic liposomal preparation comprising a lipophilic compound | Medigene AG (DE) | 2009-10-14 | — | — | EP | disclosed |
| EP-1530465-B1 | METHOD OF PRODUCING A CATIONIC LIPOSOMAL PREPARATION COMPRISING A LIPOPHILIC COMPOUND | MEDIGENE AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20050202076-A1 | Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes | MEDIGENE ONCOLOGY GMBH | 2005-09-15 | — | — | US | disclosed |
| US-20050181038-A1 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system | MEDIGENE AG (DE) | 2005-08-18 | — | — | US | disclosed |
| EP-1530465-A1 | METHOD OF PRODUCING A CATIONIC LIPOSOMAL PREPARATION COMPRISING A LIPOPHILIC COMPOUND | MediGene Oncology GmbH (DE) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004002468-A1 | METHOD OF PRODUCING A CATIONIC LIPOSOMAL PREPARATION COMPRISING A LIPOPHILIC COMPOUND | MEDIGENE ONCOLOGY GMBH (DE) | 2004-01-08 | — | — | WO | disclosed |
| EP-1374864-A1 | Amphiphilic taxane compositions | Munich Biotech AG (DE) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050202076-A1 | Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes | LPXN, TREH, LIPA | FDPS 1669/4885SMPD1 65/4885LPAR1 592/4885 |
| US-20140205657-A1 | METHOD OF PRODUCING A CATIONIC LIPOSOMAL PREPARATION COMPRISING A LIPOPHILIC COMPOUND | LIPA, LPXN, LCLAT1 | FDPS 2210/4885SMPD1 35/4885LPAR1 67/4885 |
| US-20050181038-A1 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system | SLC7A1, NPC1L1, LIPA | FDPS 2471/4885SMPD1 45/4885LPAR1 40/4885 |
| US-20100178243-A1 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system | SLC7A1, NPC1L1, LIPA | FDPS 2471/4885SMPD1 45/4885LPAR1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.